Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2021-04-09 Annual Report
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
20-F
Annual Report FY 2020
2021-04-09 English
FORM 6-K
Regulatory Filings
2021-04-07 English
Grifols, S.A. informa que ha cerrado la transacción para adquirir 7 centros de donación de plasma en Estados Unidos de la empresa Kedplasma, LLC.
Regulatory Filings Classification · 99% confidence The document is a formal communication from Grifols, S.A. in Spanish, referencing compliance with Article 227 of the Spanish Securities Market Law ('Ley del Mercado de Valores'). It announces a specific corporate action: the closing of a transaction to acquire 7 plasma donation centers in the US for $55.2 million. This is a material event disclosure. Since it details a significant corporate transaction (acquisition/expansion) that affects capital structure or operations, but is not a standard periodic report (10-K, IR), dividend notice (DIV), or director dealing (DIRS), it fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Given the nature of the announcement—a specific acquisition financed with own resources (no new debt)—'Capital/Financing Update' (CAP) is the most precise fit, as it relates directly to capital structure and expansion funding. The document is short and serves as an immediate disclosure of a transaction.
2021-04-07 Spanish
Información periódica bajo el programa de recompra de acciones
Transaction in Own Shares Classification · 98% confidence The document is a communication from Grifols, S.A. titled "OTRA INFORMACIÓN RELEVANTE" (Other Relevant Information) regarding the execution of its share repurchase program ("programa de recompra de acciones propias"). It details the number of shares bought and the prices paid between March 30 and April 6, 2021, and includes a detailed annex of individual transactions. This activity—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The filing code for this activity is POS.
2021-04-06 Spanish
Información periódica bajo el programa de recompra de acciones
Transaction in Own Shares Classification · 98% confidence The document is a formal communication from Grifols, S.A. to the CNMV (Comisión Nacional del Mercado de Valores) under the heading 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The core content details transactions carried out under a share repurchase program ('programa de recompra de acciones propias') during a specific period (March 23 to March 29, 2021). This type of filing, reporting the company's own transactions in its shares, directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general earnings release (ER), an annual report (10-K), or a management discussion (MDA). It specifically details the execution of share repurchases.
2021-03-29 Spanish
Información periódica bajo el programa de recompra de acciones
Transaction in Own Shares Classification · 98% confidence The document is a communication from Grifols, S.A. titled "OTRA INFORMACIÓN RELEVANTE" (Other Relevant Information). The core content details transactions carried out under a share repurchase program ("programa de recompra de acciones propias") during a specific period (March 12 to March 22, 2021). It explicitly references compliance with EU regulations regarding market abuse and share repurchase programs. The key action described is the company buying back its own shares. This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase reports.
2021-03-22 Spanish

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.